GELS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.484

Open

0.484

VWAP

0.48

Vol

1.34K

Mkt Cap

5.19M

Low

0.484

Amount

651.14

EV/EBITDA(TTM)

--

Total Shares

10.71M

EV

7.73M

EV/OCF(TTM)

--

P/S(TTM)

44.37

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

Show More

Events Timeline

(ET)

2026-02-11

09:00:00

Gelteq and Healthy Extracts Sign Strategic Partnership MOU

2026-01-13 (ET)

2026-01-13

09:20:00

Gelteq Oral Gel Platform Increases CBD Bioavailability by Over 22%

2025-12-16 (ET)

2025-12-16

09:20:00

Gelteq Announces New Partnership with Hong Kong Flag Football Program

2025-12-09 (ET)

2025-12-09

09:20:00

Gelteq Enters Three-Year Sales Agreement with Shenzhen Mana, Expected Revenue of $1.3 Million

2025-12-05 (ET)

2025-12-05

10:50:00

Gelteq Announces Preclinical Findings Demonstrating Effectiveness of Gel Platform

2025-11-24 (ET)

2025-11-24

08:43:18

Gelteq Reports Encouraging Preclinical Findings for Its Gel Formula

2025-10-23 (ET)

2025-10-23

09:09:32

Gelteq Launches Preclinical Trial for Drugs with Low Solubility

2025-10-09 (ET)

2025-10-09

08:15:45

Gelteq Partners with Melbourne Health for Product Development and Profit Sharing Agreement

2025-09-12 (ET)

2025-09-12

07:32:16

Gelteq Fuels Healthy Extracts' Product Launches in the U.S.

2025-07-17 (ET)

2025-07-17

08:36:25

Gelteq announces agreement with IDT Australia to secure manufacturing facility

News

Newsfilter

05-20Newsfilter

Gelteq Initiates First Clinical Trial for Veterinary Drug Candidate

seekingalpha

05-12seekingalpha

Gelteq Secures $3.5 Million Debt Financing for Growth

Benzinga

Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%

Benzinga

U.S. Stock Futures Decline as CPI Rises 2.7% Year Over Year

Benzinga

Bank of America Expected to Report $0.96 EPS on $27.87 Billion Revenue

Benzinga

Gelteq Ltd. (NASDAQ:GELS) Shares Surge 69.25% on Positive Preclinical Results

Valuation Metrics

The current forward P/E ratio for Gelteq Ltd (GELS.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Gelteq Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding GELS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Gelteq Ltd (GELS) stock price today?

The current price of GELS is 0.484118 USD — it has increased 0

What is Gelteq Ltd (GELS)'s business?

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

What is the price predicton of GELS Stock?

Wall Street analysts forecast GELS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GELS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Gelteq Ltd (GELS)'s revenue for the last quarter?

Gelteq Ltd revenue for the last quarter amounts to 0.00 USD, decreased

What is Gelteq Ltd (GELS)'s earnings per share (EPS) for the last quarter?

Gelteq Ltd. EPS for the last quarter amounts to -0.12 USD, increased 20.00

How many employees does Gelteq Ltd (GELS). have?

Gelteq Ltd (GELS) has 7 emplpoyees as of June 03 2026.

What is Gelteq Ltd (GELS) market cap?

Today GELS has the market capitalization of 5.19M USD.